Imperial and Crick cancer drug spinout raises £90m to begin clinical development
Myricx Bio is bringing new therapeutic possibilities to the highly promising area of antibody-drug conjugates for treating cancer.
Major cause of inflammatory bowel disease discovered
UK researchers have discovered a new biological pathway which drives inflammatory bowel disease (IBD) and could be targeted with existing drugs.
Bendy X-rays and DMT infusions: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
Yeast production and engineering fellowship: News from the College
Here’s a batch of fresh news and announcements from across Imperial.
New study to explore how well COVID-19 vaccines protect dialysis patients
A new study will assess how well COVID-19 vaccines work in people who attend hospital for their dialysis treatment (haemodialysis).
Cancer-causing HTLV-1 virus hijacks cellular machinery to establish infection
Scientists have used a cutting-edge visualisation technique to show how the human T-cell lymphotropic virus, type 1 (HTLV-1) infects immune cells.
Researchers offered support and funding to launch tech startups addressing pain
An Imperial-led accelerator is set to help researchers turn ideas for medical technologies into ventures aimed at understanding and treating pain.
COPD care and composite creations: News from the College
Here’s a batch of fresh news and announcements from across Imperial.
Future neuroscientists join forces at Crick Partnership student conference
Master's students from Imperial, KCL and UCL gathered at the Francis Crick Institute last week for the inaugural Future of Neuroscience conference.
Sir Paul Nurse delivers Hammersmith and White City Distinguished Lecture
Nobel laureate Sir Paul Nurse delivered Imperial's Hammersmith and White City Distinguished Lecture this week.
